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Background: Hypothalamic neuropeptide Y (NPY) and two immediate early genes, c-fos and c-jun, have been found
to be involved in regulating the appetite-suppressing effect of amphetamine (AMPH). The present study investigated
whether cerebral catecholamine (CA) might regulate NPY and POMC expression and whether NPY Y1 receptor (Y1R)
participated in activator protein-1 (AP-1)–mediated feeding.
Methods: Rats were given AMPH daily for 4 days. Changes in the expression of NPY, Y1R, c-Fos, c-Jun, and AP-1 were
assessed and compared.
Results: Decreased CA could modulate NPY and melanocortin receptor 4 (MC4R) expressions. NPY and food intake
decreased the most on Day 2, but Y1R, c-Fos, and c-Jun increased by approximately 350%, 280%, and 300%,
respectively, on Day 2. Similarly, AP-1/DNA binding activity was increased by about 180% on Day 2. The expression
patterns in Y1R, c-Fos, c-Jun, and AP-1/DNA binding were opposite to those in NPY during AMPH treatment. Y1R
knockdown was found to modulate the opposite regulation between NPY and AP-1, revealing an involvement of
Y1R in regulating NPY/AP-1–mediated feeding.
Conclusions: These results point to a molecular mechanism of CA/NPY/Y1R/AP-1 signaling in the control of
AMPH-mediated anorexia and may advance the medical research of anorectic and anti-obesity drugs.
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Amphetamine (AMPH) is a well-known psychostimulant.
Although AMPH has a neurotoxic effect because of the
production of free radicals and oxidative damage in the
brain [1,2], AMPH can be clinically applied to improve
some nervous disorders, such as childhood attention-
deficit/hyperactivity disorder [3], multiple sclerosis patients
with memory impairment [4], stroke or brain injury [5],
and Alzheimer’s disease [6]. Regarding the effect on appe-
tite, AMPH recently served as a prototype for the research
on anorectic drugs for the development of subsequent
anti-obesity drugs [7,8]. Therefore, the mechanisms behind
the anorectic, psychomotor, and neurotoxic effects of
AMPH have been investigated extensively.* Correspondence: dykuo@csmu.edu.tw
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reproduction in any medium, provided the orThe mechanism underlying the appetite-suppressing ef-
fect of AMPH is relevant to the central release of
catecholamine (CA), which may act on hypothalamic NPY-
containing neurons to suppress appetite [9]. Both neuro-
peptide Y (NPY) and proopiomelanocortin (POMC) are
involved in regulating AMPH-induced anorexia [10,11].
However, it is still unknown whether cerebral CA is
involved in this regulation, we hypothesized that decreased
CA could simultaneously modulate NPY and POMC
expression in AMPH-treated rats.
Hypothalamic NPY is a highly conserved neuropeptide
that contributes controlling daily feeding behavior, energy
homeostasis [12,13], stress [14], and anxiety [15]. Thus,
NPY and its receptors have been implicated in various bio-
logical functions and neuronal disorders, such as epilepsy,
obesity, and anxiety. NPY acts on at least five receptors, in-
cluding the Y1, Y2, Y4, Y5, and y6 subtypes, which are class
I G-protein–coupled receptors [16]. Of these subtypes, thetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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suggested to mediate the effect of NPY-mediated feeding
[17,18]. Studies have shown that both Y1R and Y5R knock-
out mice have higher body weight, increased food intake,
and greater adipose deposition [19,20]. Recently, reports
revealed that hypothalamic Y1R, but not Y5R, was involved
in the regulation of AMPH-induced anorexia [21] or phen-
ylpropanolamine (PPA)-induced anorexia [22], revealing a
major role of Y1R in CA-mediated anorexia.
In the nervous system, there are two immediate early
genes (IEG), c-fos and c-jun, that can be induced by
extracellular signaling, including hormones, neurotrans-
mitters, and drugs of abuse [23]. The cascade of c-Jun
and c-Fos signaling can be activated by AMPH [24-26].
The activator protein-1 (AP-1) binding protein, which is
formed as a Fos/Jun heterodimer or a Jun/Jun homodimer
of IEG, is a representative transcriptional factor that is ac-
tivated in response to signal transduction cascades [27].
Thus, AP-1 activity is increased in several brain regions
after methAMPH treatment [28], and AP-1 DNA binding
activity is associated with enhanced motor behavior in
AMPH-treated rats [29]. Previously, we reported that
c-Fos/c-Jun participated in NPY-mediated appetite regula-
tion in AMPH-treated rats [26]. However, it is still unclear
whether Y1R and AP-1 signaling participated in the regu-
lation of the NPY-mediated feeding. We hypothesized that
the activation of NPY/Y1R/AP-1 signaling might be in-
volved in the control of AMPH-induced anorexia.
Methods
Animal treatments
Male rats of the Wistar strain, with a weight of 200 ~
300 g, were obtained from the National Laboratory Animal
Center. They were housed individually in cages, main-
tained at a temperature of 22 ± 2°C, in a room with a 12-
hour light-dark cycle (light on at 6:00 AM), and habituated
to frequent handling. The administration of drugs and the
checking of food intake were performed every day at the
beginning of the dark phase (6:00 PM). All procedures
were carried out in accordance with the Guide for the Care
and Use of Laboratory Animals as adopted by the National
Institutes of Health. This study has been approved and
reviewed by the National Science Council, Taiwan, ROC.
Experimental procedures
To examine the effect of daily AMPH (d-amphatamine, a
sulphate salt dissolved in saline) on feeding behavior, rats
(N = 8 for each group) were injected intraperitoneally (i.p.)
with various doses of AMPH (0, 2 or 4 mg/kg) once a day
for 4 days. The first time AMPH was given was at the end
of Day 0 (at 6:00 pm), which was regarded as the begin-
ning of Day 1. The intake data were calculated as the total
amount of food during the previous day. To examine the
effect of endogenous CA on daily AMPH anorexia, α-methyl-para-tyrosine (AMPT) was given prior to the treat-
ment of 4-mg/kg AMPH once a day for 4 days. In a previ-
ous study, AMPT, an inhibitor of tyrosine hydroxylase,
was given with the dose of 40 mg/kg (i.p.) into rats twice a
day at 6 and 2 h prior to AMPH administration in order
to inhibit CA synthesis in the brain [30]. AMPT treatment
can efficiently decrease CA content in the brain as de-
scribed in our previous report [9]. The treatment of
AMPT alone has no significant effect on feeding behavior.
To determine the effect of pretreatment with Y1R anti-
sense oligodeoxynucleotide (ODN) on anorectic response
of AMPH, rats (N = 8 for each group) were given intracer-
ebroventricularly (i.c.v.) with missense (control group) or
antisense (20 μg in a 10-μl vehicle) once a day at 1 h before
AMPH (4 mg/kg; i.p.) for 4 days. Before AMPH treatment,
rats were given with similar dose of missense (or antisense)
daily for 2-3 days until the response of feeding behavior
was changed slightly in antisense group. This was due to
the fact that either continuous or repeated injections of
antisense might be necessary to maximize behavioral effect
and especially to block the synthesis of constitutively active
gene product [31,32].
To assess the effect of daily AMPH on hypothalamic
NPY, Y1R, c-Fos, and c-Jun, levels, rats (N = 8 each group)
were given with AMPH (0 or 2 mg/kg; i.p.) once a day for
1, 2, 3 or 4 days depending on the group of rats. Rats were
divided into 5 groups (N = 8 for each group) according to
the day they were to be sacrificed. Rats received AMPH at
40 min prior to being anesthetized (pentobarbital, 30 mg/
kg, i.p.) and decapitated to remove hypothalamus from the
brain immediately, which was then subjected to determina-
tions of protein levels or stored at –80°C until further use.
To determine the effect of AMPH on AP-1/DNA bind-
ing activity, rats were given with the AMPH (4 mg/kg; i.p.;
N = 6-8 each group) daily for 4 days at the beginning of
dark phase (at 6:00 PM). At 40 min after daily AMPH
treatment, the hypothalamus was removed daily to deter-
mine AP-1/DNA binding activity by a technique of chro-
matin immunoprecipitation (ChIP) assay.
To examine the effect of Y1R antisense (or missense) on
NPY, c-Fos, c-Jun, and Y1R levels in AMPH-treated rats,
rats (N = 8 for each group) were infused daily with anti-
sense or missense (20 μg in a 10-μl vehicle; i.c.v.) at 1 h
before daily treatment with 2 mg/kg AMPH for 4 days.
Before AMPH treatment, rats were infused with similar
dose of antisense (or missense) daily for 2-3 days. At
40 min after antisense (missense) and/or AMPH treat-
ment, rat’s hypothalamus was removed for the determin-
ation of protein levels.
To determine the effect of Y1R antagonist on AMPH-
induced anorexia and on the changes of hypothalamic
NPY, c-Fos, and c-Jun levels during a 24-h testing period,
rats (N = 8 for each group) were pretreated with BIBP-
3226 at 30 min before 2 mg/kg AMPH treatment. BIBP-
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not to have any effect at the Y2, Y4, and Y5 receptors [33]
and can significantly reduce NPY-induced feeding [34].
We therefore studied the effect of BIBP-3226 (80 nmole,
i.c.v.; MW 473.6) on AMPH-induced effects. Rats received
BIBP and/or AMPH at 40 min prior to the removal of
hypothalamus. The BIBP-3226 is dissolved in artificial
cerebrospinal fluid (aCSF) solution containing 140 mM
NaCl, 3.35 mM KCl, 1.15 mM MgCl2, 1.26 mM CaCl2,
1.2 mM Na2HPO4, 0.3 mM NaH2PO4, pH 7.4.
Lateral ventricular cannulation
A surgery of rat was performed under anesthesia with
pentobarbital (30 mg/kg; i.p.) using stereotaxic apparatus
(Kopf Model 900, Tujunga, CA, USA). The target of can-
nulation was close to the junction between the right lateral
ventricle and the third ventricle (coordinates: 0.8 mm pos-
terior to Bregma, 1.5 mm from the midline, and 3.5 ~
4.0 mm below the dura) [35]. A 23-g stainless steel guide
cannula was implanted and secured to the skull using
stainless-steel screws and dental cement. A correct place-
ment was confirmed by observing a transient and rapid in-
flow of vehicle in PE tube connected with a 28-g injector
cannula. The cannula was then occluded with a 28-g sty-
let. For ICV infusion of antisense, the stylet was replaced
with a 28-g injector cannula extending 0.5 mm below the
tip of guide cannula. Behavioral testing began at 1 week
after the surgery. For all experiments, verification of can-
nula placement was done by the administration of angio-
tensin II (100 ng/rat) and by the histological checking.
Angiotensin II reliably induced water drinking in non-
deprived rats when administered into the ventricles [36].
Only data from rats drinking more than 10 ml within
30 min were included in this study.
ICV injection of Y1R antisense
Y1R antisense ODN was administered as described pre-
viously [37] except for the change of dosage and the
modification of sequence at both ends. Briefly, 40 μg of
YlR-antisense or control (missense) dissolved in 20 μl sterile
vehicle was injected twice daily (20:00 PM and 8:00 AM)
for three consecutive days, since this treatment has been
shown to selectively reduce Y1R density, with no effects of
the sense ODN [37]. The base sequences were: antisense,
5′-GGAGAACAGAGTTGAATT-3′ and missense, 5′-AA
TTCAACTCTGTTCTCC-3′. We used ODNs that were
phosphorothioate-modified (S-ODN) only on the three ter-
minal bases of both the 5′ and 3′ ends, because these S-
ODNs had been shown to produce sequence-specific
effects without detectable toxicity in brain region and was
regarded as a well-established agent in several vertebrate
systems [32,38]. Moreover, we selected a dose of 20 μg of
antisense S-ODN because previous studies had shown that
i.c.v. injections of this amount of antisense optimallyinhibited the expression of genes and the activity of feeding
behavior [39,40]. Both antisense and missense S-ODN were
dissolved in aCSF solution.
Western blotting
Protein samples extracted from hypothalamus tissue were
separated in a 12.5% polyacrylamide gel, transferred onto
a nitrocellulose membrane and then incubated separately
with specific antibodies against NPY, Y1R, c-Fos, c-Jun,
and β-actin. The β-actin was used as an internal standard
of protein. After incubation with horseradish peroxidase
goat anti-rabbit IgG, the color signal was developed by 4-
chloro-1-napthol/3,3′-diaminobenzidine, 0.9% (w/v) NaCl
in Tris-HCl. Relative photographic density was quantified
by scanning the photographic negative film on a Gel
Documentation and Analysis System (AlphaImager 2000,
Alpha Innotech Corporation, San Leandro, CA, USA).
Chromatin immunoprecipitation (ChIP) assay
ChIP analysis was performed as described previously [41].
Chromatin isolation and ChIP assay were performed by
using the EZ-ChIP chromatin immunoprecipitation kit
(Millipore, Bedford, MA, USA) according to the manufac-
turer’s instructions. Briefly, after fixation of hypothalamus
tissue with 1% formaldehyde, each soluble chromatin was
digested and isolated using EZ-Zyme lysis buffer and EZ-
Zyme enzymatic cocktail, 4 × 106 cells that were isolated
from chopped mouse brain tissue and then 2.5 mol/L gly-
cine solution was added to stop the cross-linking reaction.
The chromatin fraction was diluted 10-fold with ChIP di-
lution buffer and precleared with salmon sperm DNA in a
protein G agarose. The precleared chromatin solution was
divided and used in immunoprecipitation assays with anti-
c-Jun, anti-c-Fos and anti-rabbit IgG antibodies. Following
multiple washes, the antibody-protein-DNA complex was
eluted from beads. After reversal cross-link incubation,
protein and RNA were removed by proteinase K and
RNase A. Purified DNA was subjected to polymerase
chain reaction (PCR) with primers specific for AP-1-
binding sites upstream of the transcriptional start site. The
sequences of the PCR primers used are as follows: AP-1,
5′-CCT AAG GCA TAG AGC AAT GAC-3′ (sense) and
5′-GGT GAG AAA CAT GAC TAG GTG-3′ (antisense).
Extracted DNA (2 μl) was used for 45 cycles of amplifica-
tion in 50 μl of reaction mixture under the following condi-
tions: 95°C for 30s, 58°C for 60s, and 72°C for 30s.
The PCR products were analyzed by 2% agarose gel
electrophoresis [42].
Drugs, chemicals and reagents
Chow (LabDiet) was purchased from PMI Nutrition Inter-
national (Brentwood, MO, USA). AMPH, AMPT, BIBP-
3226, Tris-HCl solution, angiotensin II, ethidium bromide
were purchased from Sigma-Aldrich (St. Louis, MO, USA);
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Santa Cruz Biotechnology (Santa Cruz, CA, USA), those
against AP-1 and c-Jun antibodies were purchased from
Cell Signaling Technology, (Beverly, MA, USA), while that
against β-actin was purchased from Gibco BRL, Life Tech-
nologies, Inc., (Rockville, MD, USA). Anti-NPY1R poly-
clonal antibodies were purchased from Novus Biologicals,
LLC (Littleton, CO, USA). TRIZOL reagent (Life Tech-
nologies, Inc., Grand Island, USA) was used in tissue
homogenization. Antisense Y1R was synthesized by Proligo
Pty Ltd (Singapore).
Statistical analysis
Data were presented as the mean ± SEM. Two-way or
one-way ANOVA followed by Dunnett’s test was used to
detect significances among groups. P < 0.05 was consid-
ered to be statistically significant.
Results
The effect of AMPT pretreatment on AMPH-induced
appetite suppression and NPY/MC4R expression
The change of food intake following AMPH treatment
is shown in the upper panel of Figure 1. Statistical ana-
lysis by two-way ANOVA revealed significant dose-
dependent [F(2,21) = 8.21, p < 0.05] and time-dependent
effects [F(4,35) = 4.58, p < 0.05]. Followed by Dunnett’s
test, it revealed that daily AMPH (2 mg/kg) produced
marked decreases in food intake from Day1 to Day 2
(anorectic effect) and a gradual return to normal intake
from Day 2 to Day 4 (tolerant effect), but daily AMPH
(4 mg/kg) produced a continuous anorectic response
during a 4-day period of time. Results showed in the
lower panel of Figure 1 revealed that there was a signifi-
cant difference between AMPH (4 mg/kg) group and
AMPT +AMPH (4 mg/kg) group, indicating that AMPT
could reverse AMPH-induced anorexia to normal level.
Furthermore, the effect of AMPH (2 mg/kg) on Day 4 was
significantly higher than that on Day 2, revealing that
2 mg/kg AMPH could induce gradually the tolerant effect.
However, with a dose of 4 mg/kg AMPH, it could produce
a continuous anorectic response during a 4-day period of
drug treatment. The effect of AMPH on body weight
change was in consistence with the alteration of feeding
[8,40]. Based on these findings, AMPH (4 mg/kg) was
employed for studies of AMPT/AMPH co-administration
and Y1R antisense/AMPH co-administration since it
could exert a greater anorectic effect which was more suit-
able than AMPH (2 mg/kg) for the examination of block-
ing effect of AMPTand Y1R antisense.
Effects of AMPH on NPY, Y1R, c-Fos and c-Jun expression
Results shown in Figure 2 revealed that daily AMPH re-
sulted in a significant decrease of NPY during AMPH
treatment, which was in accordance with the response offeeding response. However, daily 2 mg/kg AMPH resulted
in the increases of c-Fos, c-Jun, and Y1R levels, which was
expressed reciprocally to NPY level, compared to the con-
trol. Statistical analysis with one-way ANOVA indicated a
decrease of NPY contents [F(4,35) = 5.74, p < 0.05] from
Day 1 to Day 3 with a biggest decrease of about 55% on
Day 2. However, it revealed a significant increase of c-Fos
[F(4,35) = 7.12, p < 0.05], c-Jun [F(4,35) = 6.25, P < 0.05],
and Y1R [F(4,35) = 4.57, p < 0.05] with a maximum in-
crease of about 280%, 300% and 350%, respectively, on
Day 2 compared to the control group. These results re-
vealed that NPY was decreased and expressed in a manner
reciprocal to that of Y1R, c-Fos, and c-Jun during AMPH
treatment.
The effect of AMPH on AP-1/DNA binding activity
Results shown in Figure 3 reveal that AMPH can increase
AP-1 and DNA binding activity in the hypothalamus. Ana-
lysis with one-way ANOVA revealed the increases of c-Fos
from Day 1 to Day 3 [F(4,25) = 2.68, p < 0.05] and c-Jun
from Day 1 to Day 4 [F(4,25) = 2.98, p < 0.05] compared to
the control. This result revealed that AP-1/DNA binding
activity increased with the maximum response on Day 2
during AMPH treatment.
The effect of ICV injections of Y1R antisense on
AMPH anorexia
As shown in the lower panel of Figure 4, Y1R antisense
alone-treated group could slightly but not significantly in-
crease food intake from Day 1 to Day 4 compared to that
in the control group. Moreover, Y1R antisense can par-
tially reverse AMPH-induced anorexia, indicating the in-
volvement of Y1R gene during AMPH treatment. Using
two-way ANOVA to measure the effect of Y1R antisense,
significant drug-dependent [F(3,28) = 5.88, p < 0.05] and
time-dependent effects [F(4,35) = 6.35, p < 0.05] were re-
vealed. Comparing the food intake between antisense/
AMPH-treated and AMPH-treated rats, it revealed signifi-
cant effects from Day 1 to Day 4. Furthermore, it also re-
vealed significant effects from Day 1 to Day 4 if comparing
between antisense/AMPH-treated and missense-treated
(control) rats. The feeding response in missense-treated rats
was similar to that in saline-treated rats. Moreover, the an-
orectic response in missense/AMPH-treated rats was not
significantly changed when compared to that in AMPH-
treated rats. These results revealed the noninterference of
missense treatment in this study and also revealed that Y1R
knockdown could modify the feeding responses in AMPH-
treated rats.
Effects of Y1R antisense on NPY, c-Fos, c-Jun, and
Y1R expression
As shown in Figure 5, Y1R antisense by itself could reduce
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Figure 1 Effect of AMPT and/or AMPH administration on feeding behavior and hypothalamis NPY and MC4R expression. (A) The effect
of AMPT and/or AMPH administration on food intake over a 4-day period. The first injection of AMPH (0, 2 and 4 mg/kg; i.p.) was conducted at
the end of Day 0. AMPT (40 mg/kg; i.p.) was administered twice a day prior to daily AMPH (4 mg/kg). Each point represents the mean ± SEM of 8
rats. *P < 0.05 vs. the control group. #P < 0.05 vs. the AMPH (2 mg/kg)-treated group on Day 2. (B) The effect of AMPT, AMPH (4 mg/kg) or AMPT/
AMPH co-administration on NPY and MC4R expression on Day 1. Results showed Western Blots and the relative densitometric value for the
protein products. Inserted photo showed the results of NPY, MC4R, and β-actin expression. Bars were mean ± SEM. N = 6 each group. *P < 0.05 vs.
control. AMPT: α-methyl-para-tyrosine.










































































































Figure 2 Effects of daily AMPH on the expression of
hypothalamic NPY, Y1R, c-Fos, and c-Jun over a 4-day period.
Upper panel: the results of Western Blot. Lower panel: relative
densitometric values for Western Blot in control and 2 mg/kg
AMPH-treated groups. Contents of protein in AMPH-treated groups
were indicated as the percentage of the control group. Bars are the
means ± SEM. N = 8 each group. * p < 0.05 vs. control. # p < 0.05 vs.
the AMPH-treated groups.
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Y1R expression. Moreover, a pretreatment with Y1R anti-
sense in AMPH-treated rats resulted in partial restoration
of NPY, Y1R, c-Fos, and c-Jun levels toward normal,
revealing an involvement of Y1R in the regulation of NPY,
c-Fos, and c-Jun contents. Using β-actin as the internal
standard, the protein ratio of NPY, c-Fos, c-Jun, or Y1R
over β-actin in each group was calculated and compared.
By one-way ANOVA followed by Dunnett’s test, it re-
vealed that NPY levels were decreased by about 43 ± 6% in
AMPH-treated group, but increased about 15 ± 5% in
antisense-treated group compared to the control groups
[F(6,35) = 4.16, p < 0.05]. By contrast, Y1R levels were in-
creased by about 100 ± 15% in AMPH-treated group but
decreased by about 65 ± 10% in antisense-treated groups
compared to the control group [F(6,35) = 5.52, p < 0.05].
Moreover, Y1R level showed significant effect in antisense/
AMPH-treated group compared to AMPH-treated or
antisense-treated group. Similarly, c-Fos and c-Jun contents
were increased by about 105 ± 15% [F(6,35) = 4.85, p < 0.05]
and 206 ± 16% [F(6,35) = 5.56, p < 0.05], respectively, in
AMPH-treated group compared to the control group.
Moreover, c-Fos, and c-Jun levels partially reversed to nor-
mal in antisense/AMPH-treated groups compared to
AMPH-treated or antisense-treated group.Effects of BIBP-3226 pretreatment on feeding and
changes of NPY, c-Fos, and c-Jun expression
As shown in the upper panel of Figure 6, it revealed that
pretreatment with BIBP-3226 before 4 mg/kg AMPH
could attenuate an AMPH-induced anorectic response.
Statistical analysis with one-way ANOVA revealed a sig-
nificant effect [F(3,28) = 7.42, p < 0.05]. AMPH could de-
crease the food intake by 50% compared to the control
and pretreatment with BIBP-3226 before AMPH could re-
verse food intake by 50% compared to AMPH-treated
group. The food intake in control (aCSF-treated) rats was
similar to that in saline-treated rats, revealing the nonin-
terference of vehicle in this study. Moreover, the expres-
sion of feeding in BIBP-3226-treated rats was slightly but
not significantly reduced (decreased by 10% food intake)
compared to that in vehicle-treated rats, revealing that
BIBP-3226 had no significant effect on basal food intake
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Figure 3 The hypothalamus tissue was prepared for the ChIP
assay using antibodies specific for c-Jun and c-Fos.
PCR amplification using primers designed against AP-1-binding sites
was performed. Equal amounts of the soluble crosslinked chromatins
present in each PCR were confirmed by the product for input. Rabbit
polyclonal IgG was used as a negative control. Input, 1% of
sonicated cross-linked chromatins. Upper panel: the result of ChIP
analyzing AP-1/DNA binding activity. Lower panel: relative
densitometric values for ChIP assay. Contents of AP-1/DNA binding
activity were indicated as the percentage of the control group. Bars
are the means ± SEM. N = 8 each group. * p < 0.05 vs. control.
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missense/AMPH (4 mg/kg; i.p.) 
Y1R Antisense (i.c.v.)
Y1R Antisense+AMPH 
Figure 4 The effect of Y1R antisense (or missense)
pretreatment on daily AMPH-mediated food intake over a
4-day period. Daily missense or antisense treatment (20 μg/10 μl/day,
i.c.v.) was administered one hour before daily AMPH treatment.
* p < 0.05 vs. the missense groups. # p < 0.05 vs. the AMPH-treated
groups of each treatment. Bars are the means ± SEM. N = 8 per group.
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treatment alone didn’t affect the expression levels of NPY,
c-Fos, and c-Jun compared to the control group. However,
a pretreatment with BIBP-3226 in AMPH-treated rats re-
sulted in partial restorations of NPY, c-Fos, and c-Jun
levels toward normal level. Using β-actin as the internal
standard, the protein ratio of NPY, c-Fos, and c-Jun overβ-actin in each group was calculated and compared. By
one-way ANOVA followed by Dunnett’s test (P < 0.05), it
revealed that significant decrease of NPY content was ob-
served in AMPH-treated and BIBP-3226/AMPH-treated
groups compared to the control group [F(3,28) = 3.58, p <
0.05]. Moreover, BIBP-3226 could partially block NPY
decrease about 52% compared to the AMPH-treated
group. However, contents of c-Fos [F(3,28) = 4.52, p <
0.05], and c-Jun [F(3,28) = 5.11, p < 0.05] were increased
in AMPH-treated group and BIBP-3226/AMPH-treated
groups compared to the control group. Moreover, BIBP-
3226 could partially block c-Fos, and c-Jun contents by
about 50%, and 55%, respectively, compared to the
AMPH-treated group.
Discussion
Our current results have shown that cerebral CA partici-
pates in the control of NPY and MC4R expression. More-
over, both Y1R and AP-1 are involved in the regulation of
AMPH-mediated appetite suppression and that they are
increased and expressed in a pattern just opposite to the
decrease of NPY during AMPH treatment. This happens
because pretreatment with Y1R antisense (i.e., Y1R knock-
down) or BIBP 3226 (a selective Y1R inhibitor) can modu-
late the expression of NPY, c-Fos, and c-Jun. These results
show that Y1R play a functional role in regulating AP-1–
mediated appetite control in AMPH-treated rats. These
results expand our previous findings [26] and suggest that
hypothalamic CA/NPY/Y1R/AP-1 signal pathway partici-
pates in the regulation of AMPH-induced anorexia.
Daily treatment with 2 mg/kg of AMPH decreased food
intake and NPY expression during the initial two days of
this study (an anorectic effect) and, in turn, reverse this
Y1R antisense+AMPH
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Figure 5 The effect of Y1R antisense (or missense) pretreatment on AMPH-induced changes of NPY, Y1R, c-Fos, and c-Jun levels over a
4-day period. Daily missense or antisense treatments (20 μg/10 μl/day, i.c.v.) were administered one hour before daily 4 mg/kg AMPH treatment.
Results showed that Y1R antisense could partially restore c-Fos, and c-Jun levels toward normal. * p < 0.05 vs. the control (missense) groups of
each treatment day. # p < 0.05 vs. the AMPH-treated groups of each treatment day. Bars are the means ± SEM. N = 8 per group.
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http://www.molecularbrain.com/content/6/1/46effect gradually on the subsequent days, with food intake
and NPY expression returning to normal (a tolerance to
AMPH). Thus, hypothalamic NPY participated in both
the anorectic response of AMPH, which was related to a
decrease of NPY, and in the tolerant response of AMPH,
which was related to NPY restoration [43]. Moreover, ex-
pression of Y1R, c-Fos, c-Jun, and AP-1 increased during
AMPH treatment, with the maximum increase observed
on Day 2. This manner of expression was just opposite to
NPY expression, which showed the maximum decrease onDay 2. These results implied that Y1R, c-Fos, c-Jun, and
AP-1 might function in a manner opposite that of NPY
during the regulation of AMPH-evoked anorexia.
In the present study, both pretreatment with antisense
to knock down Y1R expression or with antagonist to block
Y1R activity could modulate the expression of NPY, c-Fos
and c-Jun, indicating the involvement of Y1R in the regu-
lation of NPY/AP1-mediated appetite suppression. This is
in accordance with a previous report indicating that an in-












































   
   
   

























Figure 6 Upper panel: The effect of Y1R inhibitor (BIBP-3226) on 24-h AMPH-induced appetite suppression. AMPH-induced appetite
suppression could be modulated by prior administration of BIBP-3226 (80 nmol, i.c.v.). Lower panel: The effect of BIBP-3226 on the changes of
hypothalamic NPY, c-Fos, and c-Jun in 4 mg/kg AMPH-treated rats during the first day of drug treatment. AMPH-induced changes of NPY, c-Fos,
and c-Jun could be modulated by prior administration of BIBP-3226. Contents of NPY, c-Fos, and c-Jun were indicated as the percentage of
controls. * p < 0.05 vs. the control (aCSF-treated, i.c.v.) group. # p < 0.05 vs. the AMPH-treated groups. Bars are the means ± SEM. N = 8 per group.
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cellular paraventricular nucleus, which mediates the
stimulation of NPY-induced feeding [44]. Thus, the possi-
bility that the hypothalamic NPY-Y1R-AP1 signals played
a role in the control of AMPH-mediated anorexia was
considered.
Y1R expression increased during AMPH treatment. Al-
though this increased expression was opposite to the de-
creased expression of NPY during AMPH treatment, it
was consistent with the increased expression of POMC
mRNA levels [8,11]. This result revealed that Y1R might
play an essential role that is consistent with the function
of the POMC neurons (an anorexigenic transmission) butis opposite to that of NPY neurons (an orexigenic trans-
mission). Previous evidence has revealed that NPY can in-
hibit POMC-containing neurons via a unidirectional input
from NPY to POMC [45,46]. Thus, the CA released dur-
ing AMPH treatment might at first exert its inhibitory ac-
tion on NPY neurons, which in turn increased (or
disinhibited) POMC expression via the activation of Y1R.
POMC gene expression might be changed during
AMPH treatment via Y1R/AP-1 signaling. Previously, we
had examined the effect of NPY knockdown on NPY/
Y1R/POMC signal pathway and found that NPY knock-
down could enhance the increasing effects of Y1R and
MC3R in AMPH-treated rats [8]. Recently, we have
Hsieh et al. Molecular Brain 2013, 6:46 Page 10 of 12
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NF-κB/POMC signal pathway and found that Y1R knock-
down reduce the increasing effects of Y1R, nuclear factor
kappa B (NF-κB), and MC3R in AMPH-treated rats [47].
In the present study, Y1R knockdown could reduce anor-
ectic response and NPY reduction, and reduce the increas-
ing effects of Y1R and AP-1 in AMPH-treated rats. Thus,
we suggest that NPY/Y1R/AP-1/POMC signal pathway is
involved in regulating AMPH anorexia.
The increased expression of Y1R from Day 1 to Day 3
during AMPH treatment might be related to the activation
of some transcription factors in POMC-containing neu-
rons. The Y1R gene in rodents contains multiple regula-
tory elements, such as NF-κB, AP-1, and c-AMP response
element–binding protein (CREB), which can be regulated
by neuronal activity and may participate in the regulation
of Y1R expression [48]. Thus, the expression of the Y1R
gene in the hypothalamus may change during the regula-
tion of energy balance, such as fasting, hypophagia, and
diet-induced obesity [49]. In the present study, Y1R and
AP-1 expression were increased during AMPH treatment
and this increase was just opposite to the decrease of NPY,
revealing the involvement of NPY-Y1R-AP1 signaling in
the regulation of AMPH-induced anorexia. Our previous
studies revealed that both CREB [50] and NF-κB [8] genes
in POMC-containing neurons were up-regulated and
expressed in a manner similar to that of the Y1R gene dur-
ing a 4-day period of AMPH treatment. Recently, we
found that Y1R was involved in regulating CREB [51] and
NF-κB [47] expression in AMPH or PPA-treated rats, re-
vealing the activation of Y1R/CREB and Y1R/NF-κB
signals during AMPH (or PPA) treatment. These results
implied that the activation of Y1R-AP1 signaling, perhaps
together with the co-activation of Y1R-CREB and Y1R-
NFκB signals, might function together in the modulation
of POMC gene expression during AMPH treatment.
Moreover, the co-activation of Y1R/AP-1, Y1R/CREB, and
Y1R/NFκB signals during AMPH treatment might also ex-
plain why the pretreatment with Y1R antisense or BIBP-
3226 partially blocked the effects of AMPH on c-Fos and
c-Jun levels in the present study.
The co-activation of Y1R and AP-1 during AMPH treat-
ment might be involved in the regulation of oxidative
stress in the brain. Our previous reports revealed that sev-
eral anti-oxidative enzymes, such as superoxide dismutase
[26] and glutathione peroxidase [10], are elevated and
expressed similar to Y1R and AP-1 expression, which was
seen in the present study during the 4-day AMPH treat-
ment period. Moreover, brain NPY is associated with the
anti-stress response [52], and brain Y1R can be modulated
by different kinds of brain insults, such as stress and seiz-
ure activity [48,53]. Furthermore, AP-1 can be rapidly in-
duced by brain injury or drug treatment [54,55] and rats
treated with methAMPH might cause prolonged increaseof AP-1 because oxygen-based free radicals are known
activators of AP-1 [56]. Thus, NPY-Y1R-AP1 signal
transduction in the brain might play a functional role in
anti-oxidative stress in AMPH-treated rats. As the
stress hormone glucocorticoid can modulate both Y1R
[57] and AP-1 [58,59] in the brain, we suggested that
the release of endogenous NPY and the activation of
Y1R and AP-1 in the nervous system might be one of
the essential routes to activate anti-stress system, such
as the activations of POMC, glucocorticoid, and anti-
oxidative enzymes, during stress exposure in the brain.
Decreased expression of NPY-AP1 system in the hypo-
thalamus might be involved in higher levels of anorexia,
while decreased expression of NPY-AP1 system in the
amygdale might involve higher levels of anxiety. In the
amygdale, evidence has shown that decreased expression
of the NPY gene is related to the increased anxiety and
alcohol intake [15] and that c-Fos immunoreactivity is
increased after the administration of anxiogenic drugs
[60,61]. Moreover, dopamine plays an important role in
fear and anxiety by modulating the anxiogenic output of
the amygdale [62,63]. Thus, rats in a feeding state of an-
orexia were found to be similar to those in a mental
state of anxiety because both animals were in a state of
decreased NPY and increased AP-1 signaling. This could
explain why AMPH could induce both anxiety-related
effects [64] and anorectic responses [21] and why c-Fos
activation can regulate anxiety [65] and modulate an-
orexia [26] in AMPH-treated animals.
Although we didn’t detect the expression of NPY recep-
tor 2 (NPY2R), its’ possible role in the regulation of
AMPH-induced anorexia should be considered. The dele-
tion of NPY2R in the adult mouse hypothalamus leads to
transiently decreased body weight and increased food in-
take, indicating the functional role of the hypothalamic
NPY2R in controlling feeding behavior [66,67]. A recent
publication [68] has suggested that in chromaffin cells,
which are modified neuroendocrine cells all expressing
NPY and sharing some commons with hypothalamic NPY/
AgRP neurons, NPY expression is negatively regulated by
NPY2R but not NPY1R or NPY5R.
Drugs that target for NPY receptors have been devel-
oped as potential anti-obesity drugs [49,69]. Although po-
tent and selective antagonists of Y1R and Y5R have been
developed [49,70], mechanisms for signal transduction
downstream to Y1R and Y5R are not clear. The present
study provides evidence that the activation of NPY/Y1R/
AP-1 signaling in the hypothalamus might help regulate
the anorectic response of AMPH.
Conclusion
The present results suggest that cerebral CA is involved in
controlling hypothalamic NPY and MC4R expression and
that hypothalamic Y1R participates in regulating NPY/AP-
Hsieh et al. Molecular Brain 2013, 6:46 Page 11 of 12
http://www.molecularbrain.com/content/6/1/461–mediated appetite suppression. These results may fur-
ther the understanding of the role of molecular mecha-
nisms in the appetite-suppressing effect of AMPH.
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